The Centers for Disease Control and Prevention suggests screening for Trichomonas vaginalis infection might be considered in high-prevalence populations. High asymptomatic infection rates and poor sensitivity of clinical diagnosis make it difficult to estimate local prevalence. Testing of ThinPrep samples can provide an estimate of local Trichomonas vaginalis infection rates and guide screening practices.
Testing of ThinPrep samples during cervical cancer screening can provide population-level estimates of local Trichomonas vaginalis infection rates and guide screening practices per Centers for Disease Control and Prevention recommendations.
From the *Department of Pediatrics, San Antonio Military Medical Center, Fort Sam Houston, TX;
†Departments of Family Medicine and Pediatrics, Uniformed Services University, Bethesda, MD;
‡Department of Family Medicine, Fort Belvoir Community Hospital, Virginia;
§Department of Obstetrics and Gynecology, San Antonio Military Medical Center, Fort Sam Houston, Texas; and
¶Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO
Sources of Funding and Conflicts of Interest: None declared.
Disclaimer: The opinions and assertions expressed herein are those of the authors and are not to be construed as reflecting the views of the Uniformed Services University, Brooke Army Medical Center, Fort Belvoir Community Hospital, the U.S. Air Force, the U.S. Army, U.S. Navy, the U.S. military at large, or the U.S. Department of Defense.
Correspondence: David A. Klein, MD, MPH, Department of Family Medicine, Fort Belvoir Community Hospital, 9300 DeWitt Loop, Fort Belvoir, VA 22060. E-mail: email@example.com.
Received for publication June 27, 2018, and accepted September 9, 2018.